<DOC>
	<DOCNO>NCT00750919</DOCNO>
	<brief_summary>This trial 26-week , open label extension trial investigate safety explore efficacy esmertazapine participant insomnia complete protocol 21106/P05701/MK-8265-002 ( NCT00631657 ) .</brief_summary>
	<brief_title>Twenty-six Week Extension Trial Org 50081 ( Esmirtazapine ) Outpatients With Chronic Primary Insomnia ( 176003/P05721/MK-8265-007 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Sleep Disorders , Intrinsic</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<criteria>Sign write informed consent Completed clinical trial 21106/P05701/MK8265002 Any ( serious ) adverse event , medical condition require concomitant medication deem relevant exclusion trial 21106/P05071/MK8265002 judge investigator Were significantly non compliant protocol criterion procedures trial 21106/P05701/MK8265002 , judge investigator Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>